Search for a trial

A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…

Continuous low dose subcutaneous lidocaine for treatment of pneumonia in COVID*19 patients.   A randomised controlled (RCT) open*label phase III study.

The disappearance of the main symptoms of the COVID*19*induced pneumonia within 5 days after the initiation&…

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing selpercatinib (LOXO-292) to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Primary* To compare TFFS of patients with progressive, advanced, kinase inhibitor naïve, RET-mutant MTC treated with LOXO-292 versus cabozantinib or vandetanib.Secondary* To compare other efficacy outcomes, based on RECIST 1.1 criteria, observed in…

Continuous low dose subcutaneous lidocaine for treatment of the symptoms of COVID*19.   A randomised controlled open*label phase III study.

To determine the effect of lidocaine on the main symptoms of COVID-19.